Program
MK-8690
A development code. Also written as “PRA052”.
Its studies are mostly in Colitis, Ulcerative · Arthritis, Rheumatoid, led by Merck.
Furthest: phase 2, since Mar 4, 20263 company-led studies, 2 open or runningNext primary completion: Oct 19, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 32 open or running | phase 2since Mar 4, 2026 | Oct 27, 2022 | Oct 19, 2027phase 2 · NCT07895524 |
- Named in Merck’s own pipeline as
MK-8690
, phase 2, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 27, 2022First study: phase 1 study in HealthyFirst studyNCT05603182 · 96 enrolled · United States
- Mar 4, 2026Phase 2 study in Colitis, UlcerativePhase 2 reachedNCT07463183 · 100 planned · United States, Canada, Chile and more
- Oct 19, 2026Phase 2 study in Arthritis, RheumatoidNCT07895524 · 60 planned
Ahead
- Oct 19, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07895524
- Oct 28, 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07463183
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07895524Arthritis, Rheumatoid | 2 | Not yet recruiting | Oct 19, 2027 | 60 |
| NCT07463183Colitis, Ulcerative · United States, Canada, Chile and more | 2 | Recruiting | Oct 28, 2027 | 100 |
| NCT05603182Healthy · United States | 1 | Completed | Feb 21, 2024 | 96 |
How it is read
Names in the registry
- “MK-8690”, 2 entries
- “PRA052”, 1 entry
Codes read as this program: MK8690, PRA052.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.